SG Americas Securities LLC lessened its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN – Get Rating) by 2.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 98,953 shares of the company's stock after selling 2,500 shares during the period. SG Americas Securities LLC owned 0.28% of Silence Therapeutics worth $977,000 at the end of the most recent reporting period.
Separately, Citadel Advisors LLC bought a new stake in shares of Silence Therapeutics during the second quarter worth $136,000.
Get Silence Therapeutics alerts:Silence Therapeutics Stock Down 3.6 %
Silence Therapeutics stock opened at $13.02 on Thursday. Silence Therapeutics plc has a 12-month low of $7.80 and a 12-month high of $23.23. The business's 50-day simple moving average is $14.69 and its 200 day simple moving average is $12.10. The stock has a market cap of $467.26 million, a price-to-earnings ratio of -8.57 and a beta of 0.99.
Silence Therapeutics (NASDAQ:SLN – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.35. Silence Therapeutics had a negative return on equity of 361.62% and a negative net margin of 222.79%. The firm had revenue of $3.97 million for the quarter. As a group, sell-side analysts expect that Silence Therapeutics plc will post -0.88 EPS for the current year.Wall Street Analyst Weigh In
Several brokerages have recently commented on SLN. Morgan Stanley started coverage on Silence Therapeutics in a report on Friday, December 9th. They set an "equal weight" rating and a $18.00 target price on the stock. Chardan Capital decreased their price target on Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating on the stock in a report on Thursday, November 17th. Finally, HC Wainwright decreased their price target on Silence Therapeutics from $95.00 to $80.00 and set a "buy" rating on the stock in a report on Tuesday, December 6th.
About Silence Therapeutics
(Get Rating)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Articles
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.